MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today ...

The EMBOLD topline results will be presented at the American Epilepsy Society Annual Meeting at the Georgia World Congress Center, Poster Hall B2, 1.38 from 12:00-2:00 p.m. on Saturday, December 6, ...

Ezra Klein answers your questions on the year’s political lessons, the struggles of young men and handling heat on the show.

Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström ...

Detailed price information for Rapport Therapeutics Inc (RAPP-Q) from The Globe and Mail including charting and trades.

Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines ...

Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival ...

Eli Lilly and Company today announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) ...

Kite, a Gilead Company , presented a new analysis today demonstrating that second-line Yescarta® (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large ...

Even when your body is capable of high performance, interference, stress, and misalignment create an internal traffic jam.